HER2-positive patients with gastric cancer qualify for trastuzumab-based therapy and, therefore, determination of HER2 status in patient tumor tissue is of great importance prior to the administration of anti-HER2 targeted treatment. Here, ERBB2 is linked to gastric cancer.